CClinicalTrials.gg
TerminatedNCT04768634Updated Feb 7, 2024

Predicting Arrhythmogenic Risk in Congenital Heart Patients: the PRECISION Study

An interventional study of Provocative electrophysiology study in Arrhythmia in Children and Congenital Heart Disease, sponsored by Boston Children's Hospital. Terminated at 1 site in United States. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Diagnostic

Why this study was terminated
limited enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
0 Years to 18 Years
Sex
All
01

Study summary

In this research study we want to learn more about abnormal heart rhythm after cardiac surgery in children. These abnormal heart rhythms, also called arrhythmias, may occur due to several reasons after cardiac surgery. They can be due to abnormal electrical pathway or an irritable area of the heart that stimulates abnormal impulses. Regardless of the cause, arrhythmias after cardiac surgery can be a problem, extending the hospital stay, requiring additional medications and even leading to cardiac arrest.

Current practice is to monitor for arrhythmias after cardiac surgery, and to treat them if they occur. With this research, we want to investigate whether we can identify patients who will develop arrhythmia, and treat them before they occur.

Read the detailed description

This is a prospective, randomized controlled trial of provocative electrophysiology testing and prophylactic treatment of inducible SVT versus expectant management

02

Conditions studied

  • Arrhythmia in Children
  • Congenital Heart Disease
03

In context

Heart Diseases

3,640 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 46 is below the median of 100 across 1,779 interventional studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Boston Children's Hospital is the lead sponsor of 598 studies on the registry; 151 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 18 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged \< 18 years of age on admission to the cardiac intensive care unit following cardiac surgery with a predicted probability of supraventricular tachycardia >10%

Exclusion criteria

Exclusion Criteria:

  • Patients following orthotopic heart transplant, ventricular assist device implantation, primary extracorporeal membrane oxygenation cannulation, pacemaker or implantable cardioverter-defibrillator implantation or sympathectomy
  • Patients on antiarrhythmic medication at the time of surgery
  • Patients with atrioventricular conduction disease (1st degree atrioventricular block with PR interval greater than 200 ms, 2nd degree atrioventricular block or complete heart block)
  • Patients with severe ventricular dysfunction in whom therapy with beta-blocker or sotalol is deemed contra-indicated by the primary team
  • Patients with absent or non-functioning atrial pacing wires
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • No intervention
    Observation

    Patients will be observed for arrhythmias and treated if they occur.

  • Experimental
    Testing

    Patients will undergo provocative electrophysiology testing, and antiarrhythmic medication considered if arrhythmias can be induced.

    Diagnostic Test: Provocative electrophysiology study

Interventions

  • Diagnostic testProvocative electrophysiology study

    Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.

06

What researchers measure

Primary outcomes

  1. Number of patients with supraventricular tachycardia

    Number of days post-operatively at time of supraventricular tachycardia

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

Secondary outcomes

  1. Number of patients with adverse events related to provocative electrophysiology testing

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

  2. Number of patients with sustained supraventricular tachycardia

    Number of days post-operatively at time of sustained supraventricular tachycardia

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

  3. Number of patients with other tachyarrhythmias

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

  4. Number of days post-operatively at time of extubation

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

  5. Number of days post-operatively in the intensive care unit

    Time frame: Though hospital discharge

  6. Number of days in the hospital

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

  7. Number of patients with adverse events related to antiarrhythmic treatment

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

  8. Number of patients with major adverse cardiac events (including need for CPR, ECMO or death)

    Time frame: Through hospital discharge after cardiac surgery, or up to 90 days

  9. Number of patients with supraventricular tachycardia after hospital discharge

    Time frame: 12 months

07

Study locations

1 site
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04768634
Lead sponsor
Boston Children's Hospital
Collaborators
American Heart Association, The Children's Heart Foundation
Responsible party
Audrey Dionne (Pediatric Cardiologist, Boston Children's Hospital) — Principal investigator
First posted
Feb 24, 2021
Start date
Mar 23, 2021
Primary completion
Feb 6, 2024
Completion
Feb 6, 2024
Last update
Feb 7, 2024

Study contacts

Audrey Dionne, MD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion